| Popis: |
Members of Enterobacteriaceae family are important causative agents of several infections. Extended spectrum beta-lactamase (ESBL) producing species are serious threats to therapeutic efficacy. Ertapenem is a new carbapenem resistant to inactivation by most ESBL’s and has the advantage of single daily use. The aim of the study is to test in vitro activity of ertapenem, that is not available in Turkey, against ESBL producing and nonESBL producing Enterobacteriaceae isolates by disk diffusion method and to compare its activity with the other carbapenems. The resistance rates of ertapenem, meropenem and imipenem were 1.65%, 1.24%, and 1.24% for ESBL producing isolates and 2.46%, 0.49%, and 0.98% for non-ESBL producing isolates, respectively. According to these results, it was determined that the in vitro activity of ertapenem was similar with other carbapenems against both ESBL producing and non-ESBL producing microorganisms (p= 0.90 and p= 0.19, respectively). |
